STA
JAZZ icon

Summit Trail Advisors’s Jazz Pharmaceuticals JAZZ Stock Holding History

Summit Trail Advisors’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.13M Buy
25,428
+598
+2% +$131K 0.08% 151
2026
Q1 		$4.69M Sell
24,830
-985
-4% -$172K 0.07% 180
2025
Q4 		$4.39M Buy
25,815
+3,819
+17% +$585K 0.08% 151
2025
Q3 		$2.9M Buy
21,996
+7,663
+53% +$919K 0.04% 259
2025
Q2 		$1.52M Buy
14,333
+10,973
+327% +$1.19M 0.03% 336
2025
Q1 		$417K Sell
3,360
-1,016
-23% -$133K 0.01% 271
2024
Q4 		$539K Buy
+4,376
New +$516K 0.02% 207
2019
Q1 		– Sell
-15,854
Closed -$1.97M – 115
2018
Q4 		$1.97M Sell
15,854
-118
-0.7% -$17.5K 0.7% 28
2018
Q3 		$2.69M Buy
15,972
+118
+0.7% +$20.3K 0.59% 35
2018
Q2 		$2.73M Buy
+15,854
New +$2.59M 0.96% 16
2018
Q1 		– Sell
-1,175
Closed -$180K – 1070
2017
Q4 		$180K Buy
+1,175
New +$163K 0.02% 455

Other funds holding JAZZ

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

Summit Trail Advisors's JAZZ Position: Q2 2026 in Review

Summit Trail Advisors increased its Jazz Pharmaceuticals (JAZZ) stake by 2.4% in Q2 2026, buying an estimated $131K and bringing the position to 25,428 shares worth $6.13M. The position accounts for 0.08% of the portfolio, ranked #151.

Summit Trail Advisors first reported a position in JAZZ in Q4 2017 and has held it in 11 quarters since. 646 funds tracked by Wall St. Rank hold JAZZ as of Q2 2026.

  • Summit Trail Advisors held 25,428 shares of Jazz Pharmaceuticals worth $6.13M as of Q2 2026.
  • Summit Trail Advisors bought 598 Jazz Pharmaceuticals shares in Q2 2026, an estimated $131K.
  • Jazz Pharmaceuticals made up 0.08% of Summit Trail Advisors's portfolio in Q2 2026, its #151 holding.
  • Summit Trail Advisors first reported a position in Jazz Pharmaceuticals in Q4 2017 and has held it in 11 quarters since.
  • 646 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2026.

Based on Summit Trail Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.